CompletedPhase 2

Evaluation of Efficacy, Safety and Molecular Mechanism of Pentoxifylline Supplementation in Patients With Hepatic and Obstructive Jaundice

Egypt43 participantsStarted 2024-04-03

Plain-language summary

Investigating the efficacy, safety, and molecular mechanism of Pentoxifylline supplementation in improving elevated direct bilirubin level and liver function tests in patients with hepatic and post-hepatic jaundice

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients age 18-70 years old. * Patients diagnosed with jaundice and increased level direct bilirubin ≥ 3 mg/dL. Exclusion Criteria: * Pregnancy. * Nursing mothers. * Patients with increased indirect bilirubin level. * Patients who have Gilbert syndrome or Crigler Najjar syndrome. * Patients with Child Paugh C score (10-15 point). * History of intolerance and hypersensitivity to Pentoxifylline or to xanthine derivatives such as caffeine, theophylline. * Recent hemorrhage. * Patients who have risk factors potentially complicated by hemorrhage. * Taking anticoagulants or antiplatelet therapy.

What they're measuring

Change in total antioxidant capacity (TAC) level,

Timeframe: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.

Change in tumor necrosis factor alpha (TNF-α)

Timeframe: The participants will be assessed before initiation of the study (baseline), and at the end of the study up to 12 weeks.

Trial details

NCT IDNCT06944704

SponsorTanta University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-19

View on ClinicalTrials.gov More Hepatobiliary Disorders trials